Mindset Pharma to Participate in Upcoming Conferences in December 2022

Rhea-AI Summary

Mindset Pharma (OTCQB: MSSTF), a drug discovery company focused on next-generation psychedelic treatments for neurological disorders, will participate in two upcoming virtual conferences. CEO James Lanthier and CSO Joseph Araujo will join Stifel GMP’s The Future of Healthcare Conference on December 7, 2022, at 3:30 p.m. ET, and the Canaccord Genuity Symposium on December 13, 2022, at 11:00 a.m. ET. The company aims to address unmet medical needs through its innovative psychedelic compounds and partnerships, including one with the McQuade Center.

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) --  Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that James Lanthier, CEO of Mindset, and Joseph Araujo, CSO, will participate in two upcoming conferences:

• Stifel GMP’s The Future of Healthcare Conference to be held virtually on Wednesday, December 7, 2022. Mr. Lanthier and Mr. Araujo will participate in a fireside chat with Andrew Partheniou, Stifel Research Analyst, at 3:30 p.m. ET.  
  
  
• Canaccord Genuity Symposium on New Paradigms and Treatment Approaches in Mental Health to be held virtually on Tuesday, December 13, 2022. Mr. Lanthier and Mr. Araujo will present at 11:00 a.m. ET.
  

For more information about the conferences, or to schedule a one-on-one meeting with Mindset management, please contact your appropriate representative directly, or send an email to KCSA Strategic Communications at Mindset@kcsa.com.

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267
​​
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FAQ

What conferences will Mindset Pharma participate in December 2022?

Mindset Pharma will participate in Stifel GMP’s The Future of Healthcare Conference on December 7, 2022, and Canaccord Genuity Symposium on December 13, 2022.

Who are the speakers representing Mindset Pharma at the conferences?

The speakers from Mindset Pharma are CEO James Lanthier and CSO Joseph Araujo.

What is the purpose of Mindset Pharma's upcoming conference presentations?

The presentations aim to discuss the company’s innovative approaches to treating neurological and psychiatric disorders using psychedelic medications.

What is the significance of the ticker symbol MSSTF?

MSSTF is the ticker symbol for Mindset Pharma on the OTCQB market, indicating its trading presence in the stock market.

What types of medications does Mindset Pharma focus on developing?

Mindset Pharma focuses on developing novel, optimized psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders.